COMMUNIQUÉS West-GlobeNewswire

Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer
21/05/2024
Saint-Herblain (France), May 21, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the appointment of Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer (CSO) [...]
Valneva annonce la nomination du Dr Hanneke Schuitemaker en tant que Directeur Scientifique
21/05/2024
Saint-Herblain (France), le 21 mai 2024 – Valneva SE (Nasdaq : VALN; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui la nomination du Dr Hanneke Schuitemaker, Ph.D. en tant que [...]
FDA grants Breakthrough Therapy Designation to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
21/05/2024
The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the first-line setting 1 [...]
Idorsia announces changes to Idorsia Executive Committee and Board of Directors
21/05/2024
Ad hoc announcement pursuant to Art. 53 LR Jean-Paul Clozel to retire as CEO and stand for election as Chairman of the Board of Directors Mathieu Simon to stand for re-election to the Board – taking on the role of Vice- [...]
Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor
21/05/2024
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – May 21, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2024. Business highlights Viatris collaboration : [...]
Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value
21/05/2024
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – May 21, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the full year of 2023. Business highlights Sale of Idorsia Asia-Pacific [...]
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
21/05/2024
SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira ® REYKJAVIK, Iceland and PARSIPPANY, N.J., May 21, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva [...]
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
21/05/2024
SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira® REYKJAVIK, ICELAND & PARSIPPANY, NJ — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE [...]
Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer
21/05/2024
CUPID is a Phase I safety and dosimetry study of TLX592, Telix’s investigational antibody-based targeted alpha therapy for prostate cancer. Establishes proof-of-concept for Telix’s proprietary RADmAb® engineered [...]
NADP Advocates for Improved Access to Dental Benefits and Care
21/05/2024
Congress Urged to Support Technical Fix to Healthcare.gov DALLAS, May 20, 2024 (GLOBE NEWSWIRE) -- Improving access to dental benefits and care was the main objective of Advocacy in Action, the National Association of [...]
SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates
20/05/2024
MIAMI, May 20, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti- [...]
Cytek® Biosciences Adds Ability to Detect Subcellular Particles to Its Industry-Leading Cell Analysis Systems
20/05/2024
New Enhanced Small Particle (ESP™) Detection Option for Cytek Northern Lights™ and Cytek Aurora™ Systems Expands Capabilities of Small Particle Research FREMONT, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Today Cytek [...]
Aerami Therapeutics Presents New Lung Deposition Modeling Data For AER-901 in Pulmonary Hypertension at the American Thoracic Society 2024 International Conference
20/05/2024
DURHAM, N.C., May 20, 2024 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”) , a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious and rare cardiopulmonary diseases, [...]
Sanofi: Information concerning the total number of voting rights and shares - April 2024
20/05/2024
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’ [...]
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Avril 2024
20/05/2024
Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers Sanofi Société [...]
Avalyn Presents Clinical Data on AP01 for Pulmonary Fibrosis, Including Long-Term Efficacy and Imaging Biomarker Data, at ATS 2024
20/05/2024
AP01 (Inhaled Pirfenidone) Treatment Demonstrated Substantially Improved Efficacy and Tolerability Out to 3.5 Years Compared to Historical Data with Oral Pirfenidone Additional Poster Presentations Highlighted Post-hoc [...]
Codexis to Participate in TD Cowen 2nd Annual Sustainability Week
20/05/2024
REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will participate in a panel discussion titled, “Sustainable API [...]
Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024
20/05/2024
AUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new analyses of data from its [...]
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
20/05/2024
Food and Drug Administration (FDA) removed partial clinical hold following review of Phase 2 dose exploration study data Ongoing open label extension (OLE) study initially evaluating 25 mg; Larimar plans to dose [...]

Pages